Q-Med AB invites to conference call regarding Interim report January-March, 2009

Q-Med AB invites to conference call regarding Interim report January-March, 2009

Time:  	
Tuesday, April 28, 2009 at 10.15 a.m. CET.

To join the conference: 	
Swedish dial in number: + 46 (0)8 505 201 10
UK dial in number: +44 (0)20 7162 0077

Q-Med participants: 	
Bengt Ågerup, CEO
Alexander Kotsinas, CFO

The press release for Q-Med AB's Q1 report will be released at
08.00 a.m. on April 28, 2009.

The slide presentation will be available at www.q-med.com, and
Investors/Presentations.

A recorded version of the presentation will be available for seven working days
on 
tel: Sweden +46 (0)8 505 203 33 or UK +44 (0)20 7031 4064, access code: 83 26
88.	
Financial information from Q-Med during Year 2009

29 April	 
Annual General Meeting
23 July 	 
Interim Report January - June 2009 
23 October	 
Interim Report January - September 2009

Queries should be addressed to:
Camilla Schartau, Administrative Assistant & IR co-ordinator
Tel: +46 (0)733-87 14 22

Q-Med AB is a medical device company. The company develops, manufactures,
markets, and sells primarily medical implants. The majority of the products are
based on the company's patented technology, NASHA™, for the production of
stabilized non-animal hyaluronic acid. The product portfolio today contains:
Restylane® for filling lines and folds, contouring and creating volume in the
face, Macrolane™ for body contouring, Durolane™ for the treatment of
osteoarthritis of the hip and knee joints, Deflux® for the treatment of
vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children,
and Solesta™ for the treatment of fecal incontinence. Sales are made through the
company's own subsidiaries or distributors in over 70 countries. Q Med today has
just over 650 coworkers, with approximately 400 at the company's head office and
production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap
segment of the NASDAQ OMX Nordic.